Phase 3 N=1,499 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Kidney Cancer
Primary: 5-year Recurrence-free Survival (RFS) — 63; 67 percentage of paticipants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=331 Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage [%]) — -0.57; -0.54 Percentage of HbA1c — p=0.5102
Phase 3 N=137 Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Treated With Insulin
Primary: Postprandial Glucose Control — 36.18; 45.22 percentage of time in range (TIR)
Phase 3 N=292 Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Efficacy and Safety of SPN-810 on the Frequency of Impulsive Aggression (IA) Measured by the Impulsive Aggression Diary — -54.12; -51.64 Percent Change of IA behaviors…
Phase 3 N=552 Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
Malignant Melanoma
Primary: Composite Rate of Pyrexia Related Events — 7.6 Percentage of participants
Phase 3 N=149 Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age
Meningococcal Vaccine
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2 — 19.7; 7.7; 0; 14.1 Percentage of participants
Phase 3 N=1,045 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
Respiratory Syncytial Virus Infections
Primary: Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 FLU Vaccine Strains Expressed as Group Geometric Mean Titers (GMTs) at 1 Month After FLU Vaccine Dose…
Phase 3 N=1,803 Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Breast Cancer
Primary: Comparison of Anastrozole vs Tamoxifen in Premenopausal Patients With Non-metastatic Breast Cancer With Respect to Disease-free Survival (DFS) — NA; NA; NA; NA years…
Phase 3 N=370 A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
Open Angle Glaucoma or Ocular Hypertension
Primary: Mean Diurnal IOP at Month 3 — 17.5; 16.8 mmHg
Phase 3 N=240 Efficacy and Safety of Dapagliflozin in Acute Heart Failure
Heart Failure · Diabetes Mellitus, Type 2
Primary: Cumulative Change in Weight (Kilograms) Per 40mg of IV Furosemide Equivalents, Adjusted for Baseline Weight — -0.31; -0.42 kg/40mg IV furosemide
Phase 3 N=770 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
Metastatic Adenocarcinoma of the Pancreas
Primary: Overall Survival (OS) — 11.1; 9.2 months — p=0.04
Phase 3 N=57 Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD
PTSD · Alcohol Use Disorder
Primary: Heavy Drinking Days as Measured by the Time Line Follow Back (TLFB) — 10.5; 10.2; 1.1; 1.0 days — p=0.80
Phase 3 N=521 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
Breast Cancer
Primary: Pathological Complete Response (pCR) Rate — 24.5; 13.8 Percentage of participants — p=0.0021
Phase 3 N=35 Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis
Primary Hemophagocytic Lymphohistiocytosis
Primary: Overall Response at Week 8 or End of Treatment (if Earlier) — 62.9; 50.0; 73.7 Percentage of participants — p=0.0053
Phase 3 N=579 A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast Cancer
Primary: Cohort A: Progression-Free Survival (PFS) — 6.1; 7.4 months — p=0.9237